Key Takeaways
- Revenue fell 30% YoY, but the floor is visible: Q3 was a deliberate inventory-destocking quarter by global customers, and 25% price erosion in PTCs and SDAs compounded the volume softness. Management expects a gradual recovery from August 2024.
- SDA is the engine for FY25, with a clear catalyst path: Four new customer approvals, two new product approvals at the largest customer, and a fifth, potentially much larger customer in validation create a visible ramp from April to October 2024.
- New capacity is a margin drag today, the growth enabler tomorrow: The 200 KL Dahej plant is running near-idle, validating products, and incurring fixed costs that crushed absorption. Management expects this to reverse from July/August when PASC commercialization begins.
- The PTC franchise is stable despite price erosion: Export margins are intact, CY2024 business is already secured with large MNC customers, and the segment is organically growing volumes 10-15% per year, insulating it from domestic price wars.
- What to watch next quarter: Whether the three postponed agro products actually begin commercial supplies in August, whether the fourth SDA application at the large potential customer passes validation by March, and whether the Red Sea freight cost spike is absorbed within the quarter as guided.
Demand Environment & Revenue Walk
- The Q3 miss was a timing issue, not a demand destruction: Global customers, particularly in Europe, pushed 11 containers into January to avoid December invoicing for year-end inventory management. Management characterized the amount as not very significant.
- Price erosion amplified the revenue decline: PTCs saw the largest product (TBAB) drop from ₹425 to ₹250-275 per kg. SDAs experienced 25-30% price erosion driven by a raw material price drop from $18 to $10.8, with product pricing mechanically following the raw material math.
- Volume recovery is uneven but real: SDA customer #1 and the new customer #4 are back to pre-COVID volumes, nearly offsetting the Chinese customer #2 who has not bought a single kilogram in 14-15 months. The Chinese customer was historically 80-90% of customer #1's volume.
- Industry demand is bifurcated: Agrochemicals are expected to remain similar to 2023 with no pickup. Polymers and epoxies show no major change for at least six months. SDAs, pharma products, and dyes and pigments are starting to pick up.
- The Red Sea disruption is a near-term cost headwind: Freight rates to Europe have spiked from $900 to $3,500 per container. Management expects to absorb this cost for one quarter before repricing can take effect.
Chintan Shah: "Based on the discussion & their forecast for calendar year 2024, also looking at a slowly improving business sentiments, we are now quite confident to state that next two quarters we will observe gradually improving business sentiments and expect shifting of gears from August onwards i.e Q2FY25."
SDA: The Growth Engine
- Customer approvals are stacking up for a FY25 ramp: Three applications at a new, very large potential customer were formally approved with initial commercial orders received. The fourth application expects validation results by March 2024. The existing largest customer approved two new products, with the first commercializing from the June quarter and the second from October. Two additional customers (#6 and #7) were fully qualified for automotive applications with business onset from April.
- A fifth, potentially transformational customer is in the pipeline: Management disclosed that the largest potential SDA customer is still in validation and could be much larger than the current largest customer.
- The China overhang is contained: The second-largest SDA customer, based in China, has not purchased a single kilogram in over a year. Despite this, the recovery of customer #1 and the addition of customer #4 have nearly offset the lost volume.
- The long-term thesis has a shelf life, and the company is adapting: Management acknowledged that EV penetration in large commercial vehicles is 15-20 years away and hydrogen is decades away. SDA may see growth over the next 10 years, then a stable phase, then gradual decline. The company is moving into electrolytes and new SDA applications like plastic reprocessing to protect the business.
Chintan Shah: "Our second largest customer is in China, who is yet to resume buying, who has not bought a single kg product since last one year."
PASC & New Capacity: The Margin Bridge
- The Dahej plant is a fixed-cost burden today: The 200 KL reactor capacity added in April has produced only six products for validation, plus three existing products requiring revalidation for the site change. The plant incurs 24x7 cooling, chilling, and brine costs with practically no utilization, creating a severe unabsorbed overhead. Employee transport alone costs ₹24 lakhs per month across 12 buses.
- Commercialization unlocks the absorption: PASC pharma intermediates: two of three products approved by production trials, the third under user test in March, with final validation by September and commercial business from early 2025. PASC agro intermediates: two products fully approved, the third under validation, with commercial supplies from August and November 2024.
- Three agro products were postponed but are now firmed up: Originally scheduled for February/March 2024, these were pushed to July/August 2024 due to poor offtake. Customers have now started placing purchase orders, and management views the August timeline as firm.
- A new ₹70 crore CAPEX was announced for three additional agro intermediates: The plant will add 150 KL of reactors and a separate distillation unit. Design is complete, the same supply chain and construction company will execute, and a new multinational PMC team (CBRE) has been inducted. Commercialization is expected by October 2024.
- Management is confident the idle capacity scenario resolves from July/August: Once PASC production begins, the plant starts absorbing fixed costs, and the margin bridge from the current ~20% EBITDA toward the 25% target becomes realistic.
Chintan Shah: "if you look at the overhead increase that has happened in last nine months, periodically if you just compare it on a QoQ basis you will realize the steep rise in terms of your overhead costs and despite of that, at this topline, we are able to sustain is only the reason because we are seeing an artificial gain in terms of percentage margins on these products. Otherwise, we would definitely have been in trouble by now so far."
Electrolyte Salts & Emerging Businesses
- The electrolyte business is slower than anticipated but has a defined catalyst: A large customer is setting up a fully automated production line for energy storage batteries, going online in August 2024, which will increase demand drastically. That customer will add four assembly lines over 2024-2026, taking demand from X today to 14-16X over three years. Even at 50% capacity utilization, this translates to very large business over 2-2.5 years.
- A large European customer is progressing toward approval: Onset of business is expected from October 2024. Additionally, an electrolyte solution from lab scale was approved, and the company has been asked to move to pilot scale for another large opportunity.
- Photochlorination achieved its first firm approval: The first product was approved from pilot scale. Commercial equipment is installed at Dahej, and one container is expected to ship by end of March for final approval. Pilot trials faced teething issues, but the technology and catalyst are validated, with commercialization moving toward 2025.
- Continuous flow and electrolysis development is on track: Three products are expected to scale to pilot stage by June 2024. Two more continuous flow reactors are being added at the lab, one at pilot scale, and plant-scale CFR design is nearing completion.
- Flame retardants are deliberately paused: Management will not produce the first product because global pricing is artificially depressed by competitors with large bromine capacity who are selling bromine at cost. The product that was once $4.5-$8 is now $2.9, with raw material cost at $2.8. A second product has been developed, and a large Western customer has nearly agreed to a pricing mechanism based on a raw-material-plus-conversion model with a fixed margin for Tatva.
Chintan Shah: "My key competitors in this area are the people who have large capacities to produce bromine, which is the key raw material for that. So, I believe product pricing is happening globally in a way where they are only getting rid of the bromine that they produce."
PTCs & Margin Resilience
- Export PTC margins are intact despite price erosion: The largest product, TBAB, dropped from ₹425 to ₹250-275 per kg, but per-kg EBITDA margin is sustained because product pricing is linked to raw material cost. Domestic margins have eroded due to fierce competition where customers switch for even ₹5 differences, but exports represent 70% of PTC revenue and remain stable.
- CY2024 business is already secured: All major export customers have committed to PTC supplies for calendar year 2024. The segment has never been exponential, growing organically at 10-15% per year, and this year's topline degrowth is purely a price phenomenon, not a volume or customer loss issue.
- Backward integration is a strategic moat, not a cost-optimization play: Despite raw material price drops making in-house production less economical than buying, the company maintains 30% in-house production to offer customers a non-Chinese origin, indigenized, made-in-India supply chain. This is what attracted the large SDA customer opportunity.
Chintan Shah: "we continue to do that because that is our strategy and that is what we have presented to the customers that non Chinese origin raw material, absolutely indigenized, made in India and this is what a non-China supply chain is what we are offering and that is what has got them interested and we have got this opportunity with the large customer."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY24 revenue | ₹400-410 crore | FY24 full year |
| FY24 EBITDA margin | Approximately 20% | FY24 full year |
| Q4FY24 revenue | ₹105-130 crore | Q4FY24 |
| Q4FY24 EBITDA margin | 20% to 23% | Q4FY24 |
| SDA fourth application validation result | Results from the large potential customer's fourth application | By end of March 2024 |
| Photochlorination final approval shipment | One container shipped for final customer approval | By end of March 2024 |
| Continuous flow pilot scale-up | Three products scaled to pilot stage | By June 2024 |
| SDA largest customer, first new product commercialization | Commercial supplies begin | June/July quarter 2024 |
| PASC agro products commercialization | Two products begin commercial supplies | August 2024 |
| Electrolyte large customer automated line | Fully automated battery production line goes online, demand increases drastically | August 2024 |
| Idle capacity resolution | Plant begins absorbing fixed costs as PASC production starts | July/August 2024 |
| SDA largest customer, second new product commercialization | Commercial supplies begin | October 2024 |
| Electrolyte large European customer | Onset of business | October 2024 |
| New ₹70 crore agro intermediates plant | Commercialization | October 2024 |
| PASC pharma final validation | Three products formally validated | By September 2024 |
| PASC pharma commercial business | Onset of commercial supplies | Beginning of 2025 |
| Photochlorination commercialization | Moving toward commercial production | 2025 |
| FY25 revenue growth | At least 70% growth, per an analyst's math that management called justifiable | FY25 |
| BS-7 SDA commercialization | Actual commercialization begins | FY26 |
| Electrolyte customer demand scale-up | Demand reaches 14-16X of current levels across four assembly lines | Over next 3 years (2024-2026) |
| Incremental revenue over 3 years | ~₹680 crore total, with 60% from PASC (~₹200 crore) and 40% from SDA (~₹80-100 crore), per an analyst's math | Over next 3 years |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Revenue from operations | ₹84.2 cr, degrowth of 30% YoY and 13% QoQ |
| EBITDA | ₹11 cr, decline of 39% YoY and 46% QoQ |
| EBITDA margin | 13.1%, vs 14.9% in Q3 FY23 |
| PAT | ₹3.5 cr, degrowth of 70% YoY |
| PAT margin | 4.1%, vs 9.6% in Q3 FY23 |
| Other income | ₹1.2 cr |
| Exports | ₹52.5 cr, 62% of revenue from operations |
| FY24 revenue guidance | ₹400–410 cr, with EBITDA at about 20% levels |
| PTCs segment revenue | ₹24.8 cr, growth of 7% QoQ, decline of 24% YoY |
| SDAs segment revenue | ₹32.3 cr, decline of 24% QoQ and 43% YoY |
| Pharma and Agro Intermediates and Speciality Chemicals revenue | ₹25.4 cr, decline of 12% QoQ and 4% YoY |
| Electrolyte Salts revenue | ₹1.2 cr, growth of 2% QoQ, degrowth of 71% YoY |
| Employee expense (9MFY24) | 14% of revenues, vs 9% in 9MFY23 |
| CAPEX announced | ₹70 cr for one plant with 150 KL reactors and separate distillation plant, commercialization expected October 2024 |
| Deferred revenue (containers postponed) | ~₹11.4 cr, 11 containers postponed from Q3 to Q4 |